Regeneron Pharmaceuticals, Inc. (REGN) To Go Ex-Dividend on May 20th

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) declared a quarterly dividend on Wednesday, April 29th. Investors of record on Wednesday, May 20th will be paid a dividend of 0.94 per share by the biopharmaceutical company on Thursday, June 4th. This represents a c) annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Wednesday, May 20th.

Regeneron Pharmaceuticals has a dividend payout ratio of 9.6% indicating that its dividend is sufficiently covered by earnings. Analysts expect Regeneron Pharmaceuticals to earn $42.14 per share next year, which means the company should continue to be able to cover its $3.76 annual dividend with an expected future payout ratio of 8.9%.

Regeneron Pharmaceuticals Stock Up 3.0%

Shares of NASDAQ REGN opened at $707.06 on Friday. The company has a current ratio of 4.15, a quick ratio of 3.39 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $821.11. The firm has a market capitalization of $74.75 billion, a PE ratio of 17.23, a price-to-earnings-growth ratio of 1.58 and a beta of 0.40. The firm has a fifty day simple moving average of $756.81 and a two-hundred day simple moving average of $735.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s revenue was up 19.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $8.22 EPS. Equities analysts expect that Regeneron Pharmaceuticals will post 35.98 earnings per share for the current year.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q1 results beat expectations: Regeneron reported Q1 revenue up 19% to ~$3.6B and non?GAAP EPS of $9.47, beating estimates, driven by strong Dupixent demand and Libtayo. This underpins near?term top?line momentum. Reuters: Regeneron beats quarterly results
• Positive Sentiment: $3 billion buyback announced and dividend declared: Management authorized up to $3B in share repurchases and declared a $0.94 quarterly dividend, both shareholder-friendly actions that support EPS and investor returns. Seeking Alpha: buyback mention
• Positive Sentiment: Pipeline progress could drive medium?term upside: Management reported C5 program milestones (pivotal PNH enrollment complete, positive Phase III for cemdisiran in gMG) and potential multi?indication launches as soon as late?2026 — important optionality beyond core franchises. Yahoo: C5 milestones & pipeline
• Neutral Sentiment: Analyst target adjustments but mixed ratings: Several shops trimmed price targets (RBC to $762, Wells Fargo to $800, Truist to $796, Barclays to $917) while many retained buy/overweight stances — suggests analysts are tuning models post?earnings but still see upside. TickerReport/Benzinga: price target moves
• Neutral Sentiment: Analysts trimmed near?term forecasts: Firms modestly cut forecasts after Q1, reflecting product mix and competitive assumptions; important to watch updated guidance and modeling revisions. Benzinga: analysts cut forecasts
• Negative Sentiment: Market punished stock on Eylea weakness and competitive risk: U.S. high?dose Eylea sales underperformed expectations and competition in the retina market is intensifying — this drove the immediate post?earnings weakness despite the beat. Yahoo: Eylea sales miss
• Negative Sentiment: Q1 net income decline: GAAP net income fell ~10% to $727M year?over?year, reflecting some one?time items and mix; investors sensitive to margin and profitability trends may see this as a near?term headwind. Pharma?Technology: net income falls

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.